Azenta (Azenta) Change In Receivables : $13.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Azenta Change In Receivables?

Azenta's change in receivables for the quarter that ended in Mar. 2024 was $0.1 Mil. It means Azenta's Accounts Receivable declined by $0.1 Mil from Dec. 2023 to Mar. 2024 .

Azenta's change in receivables for the fiscal year that ended in Sep. 2023 was $34.0 Mil. It means Azenta's Accounts Receivable declined by $34.0 Mil from Sep. 2022 to Sep. 2023 .

Azenta's Accounts Receivable for the quarter that ended in Mar. 2024 was $154.7 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Azenta's Days Sales Outstanding for the three months ended in Mar. 2024 was 88.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Azenta's liquidation value for the three months ended in Mar. 2024 was $658.3 Mil.

Azenta Change In Receivables Historical Data

The historical data trend for Azenta's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Change In Receivables Chart

Azenta Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

-11.45

-18.76

-69.64

-31.40

33.99

Azenta Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															36.07	5.10	4.96	2.83	0.09

Azenta Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.0 Mil.

Azenta (NAS:AZTA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Azenta's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	154.668	/	159.134	*	91
=	88.69

2. In Ben Graham's calculation of liquidation value, Azenta's accounts receivable are only considered to be worth 75% of book value:

Azenta's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	821.711	-	340.626	+	0.75 * 154.668	+	0.5 * 122.351
=	658.3

Azenta Change In Receivables Related Terms

Thank you for viewing the detailed overview of Azenta's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Azenta (Azenta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BA3:Germany

Address

200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803

Website

https://www.azenta.com

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Executives

Herman Cueto	officer: EVP, Chief Financial Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes	officer: VP, Chief Accounting Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray	officer: Chief Strategy & New Business	C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin	director
Dorothy E Puhy	director	DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne	officer: SVP and GM, Life Sciences Proj	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou	officer: SVP and General Manager, Genom	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus	officer: EVP & Chief Operating Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson	officer: EVP & Chief Financial Officer	C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley	officer: Chief Human Resources Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram	officer: VP, Finance & Corp. Controller	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De	officer: Chief Commercial Officer, LS	15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka	officer: Sr. VP, General Manager	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha	officer: SVP, GM BLS-Products	15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824